Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
The Phase IIa clinical trial is open-label study evaluating Namodenoson in patients with advanced pancreatic adenocarcinoma whose disease has progressed following at least one prior line of therapy. The study is assessing the safety, clinical activity, and pharmacokinetics (PK) of Namodenoson, administered orally at a dose of 25 mg twice daily in continuous 28-day cycles. Approximately 20 evaluable patients are expected to be enrolled.
The trial is led by Prof. Salomon Stemmer, a prominent Oncologist and Key Opinion Leader at the Davidoff Center, Rabin Medical Center, Israel. Namodenoson has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.
'We are pleased to report that 50% of the planned patient cohort has already been enrolled and that Namodenoson has demonstrated a favourable safety profile,' stated Prof. Salomon Stemmer. 'There is a critical unmet need for safe and effective treatment options for patients with advanced pancreatic cancer who have exhausted standard therapies. This study gives us the opportunity to advance a novel therapeutic approach for this challenging disease, stated Dr. Sari Fishman, VP of Business Development at Can-Fite.'
Can-Fite looks forward to engaging with potential partners and collaborators at BIO 2025 as it continues to progress its clinical pipeline.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase 3 trial for psoriasis and commenced a pivotal Phase 3 trial. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b trial for the treatment of MASH, and in a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are 'forward looking statements'. Forward-looking statements can be identified by the use of forward-looking words such as 'believe,' 'expect,' 'intend,' 'plan,' 'may,' 'should' or 'anticipate' or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. For example, the Company is using forward-looking statements when it discusses the completion of the offerings, the satisfaction of customary closing conditions related to the offerings and the intended use of proceeds therefrom. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the 'Risk Factors' section of Can-Fite's Annual Report on Form 20-F filed with the SEC on April 14, 2025 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contact
Can-Fite BioPharma
Motti Farbstein
[email protected]
+972-3-9241114
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Centrus Energy (LEU) Extends 4-Day Losses on $650-Million Debt Issuance
We recently published . Centrus Energy Corp. (NYSEAmerican:LEU) is one of the worst-performing stocks on Wednesday. Centrus Energy extended its losing streak to a fourth straight day on Wednesday, slashing 13.77 percent to close at $187.44 apiece as investor sentiment was dampened by plans to raise $650 million in fresh funds from the issuance of convertible senior notes. In a statement on Tuesday, Centrus Energy Corp. (NYSEAmerican:LEU) said the notes will have a tenor of 7 years and mature in 2032, unless earlier converted into cash or shares, or both. The notes will carry interest rates and will be paid every 15th of February and August of each year, beginning February 2026, until the maturity date. Additionally, it granted the initial buyers an option to purchase up to an additional $100 million within a 13-day period from the date the notes were first issued. Copyright: 1971yes / 123RF Stock Photo Centrus Energy Corp. (NYSEAmerican:LEU) said it plans to use the proceeds for general corporate purposes. In other news, Centrus Energy Corp. (NYSEAmerican:LEU) announced the appointment of Todd Tinelli as its new chief finance officer, replacing Kevin Harrill, who stepped down to pursue other opportunities. While we acknowledge the potential of LEU as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Equinox (EQX) Hits New High as Firm Pivots to Strong Quarter
We recently published . Equinox Gold Corp. (NYSEAmerican:EQX) is one of the top performers on Thursday. Equinox soared to a new record high on Thursday, as investors took heart from expectations of a strong second half of the year, despite a dismal earnings performance in the past quarters. At intra-day trading, the company soared to a new high of $7.9, before paring gains to end the day just up by 15.17 percent at $7.82 apiece. In its updated report, Equinox Gold Corp. (NYSEAmerican:EQX) said it is officially entering a pivotal phase on expectations of strong production in the years ahead, following the completion of its acquisition of Calibre Mining Corp. Kaspars Grinvalds/ 'We expect a strong second half of the year, with production on track to meet our full-year consolidated guidance of 785,000 to 915,000 ounces and anticipate continued growth in both production and cash flow into 2026,' said Equinox Gold Corp. (NYSEAmerican:EQX) CEO Darren Hall. 'Our focus is clear as we grow into a top-tier producer—operational excellence, disciplined capital allocation, and deliver on our commitments to drive debt reduction, optimize our balance sheet, and maximize returns for shareholders,' he added. In the second quarter of the year, Equinox Gold Corp. (NYSEAmerican:EQX) dropped its net income by 93 percent to $23.8 million from $353.5 million in the same period last year, despite revenues increasing by 77.6 percent to $478.6 million from $269.4 million in the same period. In the first half, the company swung to a net loss of $51.6 million from a $310.7 million net income in the same period last year. Revenues increased by 76.7 percent to $902.4 million from $510.8 million. While we acknowledge the potential of EQX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time Magazine
2 days ago
- Time Magazine
You Can Now Vaccinate Yourself Against the Flu
When you're ready to get your flu vaccine this year, you have a convenient new option: you can skip the doctors' office or pharmacy and inoculate yourself. FluMist, a vaccine sprayed up the nose to protect people from serious influenza symptoms, is now available for anyone in the U.S. to order online and administer to themselves or others at home. FluMist, made by AstraZeneca, has been available since 2003. But even though it's relatively easy to administer, it still required a health care professional to give to people. in Sept. 2024, however, the U.S. Food and Drug Administration approved it for at-home use without a health care professional—making it the first flu vaccine that people can give themselves. Here's what to know. How does FluMist work? FluMist is the only nasal vaccine approved in the U.S. It's administered as two spritzes—one in each nostril—and stimulates antibodies against the influenza virus in the nasal passages and bloodstream to protect against serious disease. It differs from the more popular flu shot option. FluMist uses a weakened form of the influenza virus, while the flu shot contains an inactivated virus. But both annual shots help protect against the worst effects of whatever influenza strain is circulating and causing disease. Is FluMist as effective as the flu shot? For most people, the spray and shot are comparable in protecting against serious flu symptoms and hospitalization. FluMist is approved for children and adults from two to 49 years old, since studies show that it's less effective in people 50 and over; their immune systems tend to be weaker. For people over 65, health officials recommended a higher-dose flu vaccine to ensure they receive the maximum protection. Read More: When Is the Best Time to Get the Flu Shot? Ultimately, however, the biggest determinant of the efficacy of any flu vaccine is how well matched it is to the influenza strains causing disease in a given season. How do you vaccinate yourself? You can order doses for yourself or others in your household at in a program the company is calling FluMist Home. Each request is reviewed by pharmacists who partner with AstraZeneca to confirm that you and those you want to immunize are eligible for this type of influenza vaccination. Most healthy people ages two to 49 qualify. If you are eligible, the nasal sprays are shipped to your home, to arrive at a date you specify. That's important, because FluMist needs to be kept below a certain temperature in order to remain effective. Once it arrives, you can either use it immediately or store it in the refrigerator. Squirt the spray in each of your nostrils—or those of your family members—and whoever receives it will be vaccinated for the season. What are the side effects? FluMist's side effects can differ slightly from those of the flu shot. While the flu shot can cause redness and soreness at the injection site, as well as fever, muscle aches, headache and fatigue, FluMist can cause flu-like symptoms, including runny nose, congestion, sore throat, cough, fever, and muscle aches. That's because FluMist is made from weakened forms of the live virus. Read More: Cutting mRNA Research Could Be Our Deadliest Mistake Yet Does FluMist cost more? Yes, FluMist generally costs more than the flu shot. But all forms of flu vaccination are covered by insurance, so most people will pay about the same amount in any out-of-pocket costs, depending on their insurance plan. Will FluMist boost vaccination rates? Doctors and public-health experts are eager to see if the new at-home option for FluMist has an effect on vaccination rates and the number of flu cases in the coming season. Vaccination rates for flu have been declining since the pandemic, including among children. In the 2023-2024 flu season, nearly 45% of adults received at least one dose of the flu shot, compared to nearly 47% in the previous year. There was a similar drop for kids: 55% of children from six months to 17 years old got vaccinated, compared to 57.4% in the previous year. The convenience of vaccinating at home, without the need to make a doctor's appointment or wait at a pharmacy, could address some of the barriers to getting vaccinated—although it likely won't impact growing vaccine skepticism that is contributing to some of the decline in immunization rates. 'We believe firmly that vaccines play a critical role in public health,' said Elizabeth Bodin, vice president of U.S. marketing, sales, and access for respiratory and immunology at AstraZeneca, during an Aug. 14 press briefing. 'Given the reductions in vaccination rates, it's more important than ever that we bring education on the importance of vaccines and break down barriers with FluMist Home.'
